AZ HB2254

Permits licensed prescribing health professionals to prescribe, administer, or dispense long-term antimicrobial therapy (more than 4 weeks) for Lyme disease and tick-borne diseases based on clinical diagnosis, supported by patient medical history, physical examination, and/or certified laboratory testing.

Prohibits health profession regulatory boards from initiating disciplinary action against licensed prescribers for prescribing long-term antimicrobial therapy for clinically diagnosed Lyme or tick-borne diseases when treatment is documented in medical records and based on recognized evidence-based assessments, guideline recommendations, or standards of care.

Defines "Lyme or tick-borne disease" to include acute infections, late-stage or chronic infections, related complications, and other variants including borrelia and viral, parasitic, bacterial, or other infectious agents.

Preserves regulatory boards' authority to take disciplinary action against prescribers for reasons unrelated to Lyme or tick-borne disease treatment.

Known as the "Ryan Montgomery Lyme Disease Treatment Act."